# Christos Karapetis

Source: https://onco.cc/people/christos-karapetis/  
OnCo record `christos-karapetis` (Person). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

Australian medical oncologist whose landmark NEJM analysis showed KRAS mutation predicts lack of benefit from cetuximab in colorectal cancer.

## Summary

Christos (Chris) Karapetis is a Professor of medical oncology at Flinders University and Flinders Medical Centre in Adelaide and serves on the Board of Directors of the Australasian Gastro-Intestinal Trials Group. He was first author of the 2008 New England Journal of Medicine analysis of the CO.17 trial establishing KRAS mutation status as a predictive biomarker for cetuximab in advanced colorectal cancer, and has led numerous AGITG trials.

## Fields

- Kind: Person
- Last checked: 2026-09-10
- Tags: clinician-scientist; colorectal cancer; clinical trials
- Role: Board Director
- Specialisms: Medical oncology; Colorectal cancer; Biomarkers; Clinical trials

## Sources

- Society page: https://gicancer.org.au/about-us/board-of-directors/
- PubMed: https://pubmed.ncbi.nlm.nih.gov/?term=Karapetis+CS%5BAuthor%5D

## Connected records

- cancers: [Colorectal cancer](https://onco.cc/cancers/colorectal/)
- companies: [Australasian Gastro-Intestinal Trials Group](https://onco.cc/companies/agitg/)
- key papers: [K-ras mutations and benefit from cetuximab in advanced colorectal cancer](https://onco.cc/key-papers/paper-karapetis-kras-cetuximab-colorectal-nejm-2008/)

---
JSON: https://onco.cc/api/v1/entities/christos-karapetis.json